Gilead announces preclinical results for TLR7 agonist GS-9620
25 February 2016 | By Victoria White
Data from the preclinical study support continued investigation of GS-9620 as part of an HIV eradication strategy…
List view / Grid view
25 February 2016 | By Victoria White
Data from the preclinical study support continued investigation of GS-9620 as part of an HIV eradication strategy…
17 September 2015 | By Vicky White
By identifying ERManI as the target that slows the spread of HIV-1, researchers have revealed a target in which future therapies can be developed...
20 July 2015 | By Victoria White
Lower levels of cholesterol in certain immune cells may help explain why some HIV-infected people are able to naturally control disease progression...
9 July 2015 | By Victoria White
Scientists have shown that didehydro-Cortistatin A reduces residual levels of HIV virus from dormant cells, establishing a near-permanent state of latency...
26 February 2015 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced data supporting the clinical development of BMS-955176, an investigational component designed to prevent the maturation of HIV-1...
24 July 2014 | By Gilead Sciences
Gilead Sciences, Inc. announced at the 20th International AIDS Conference in Melbourne, Australia, a new agreement with the Medicines Patent Pool to expand access to Gilead’s investigational drug tenofovir alafenamide...
6 June 2014 | By Merck
MSD announced that the first patient has been enrolled in the company’s global Phase 3 clinical trial, ONCEMRK...
13 May 2014 | By Johnson & Johnson
Latest innovative collaboration from the Janssen Global Public Health group and significant contribution to Johnson & Johnson’s wider efforts to improve public health worldwide...
6 March 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company presented 24-week Phase IIb data that demonstrated similar response rates for its investigational compound...